



exactech

**equinox**

Equinox® by the Numbers

# OUR RESULTS ARE OUR STRENGTH

Innovations that have improved the art of shoulder arthroplasty:



**2011**

rTSA  
glenoid  
augments

**2012**

rTSA prosthesis  
design  
classification  
system<sup>4,5,8</sup>

**2014**

ASTM  
standard for  
rTSA glenoid  
loosening





# 15,000+ Patient Database

Since 2004, the Equinoxe Shoulder System has both evolved and remained steadfast to its founding principles and design.

Over the last 16 years, we've worked toward creating the world's largest and most established single-shoulder prosthesis database. Our portfolio highlights the strength of this data and our perpetual pursuit of innovation.

# Explore the numbers with us.



**2015**

**2016**

**2020**

**2021**

**2022**

Expanding the indications of rTSA with the Humeral Reconstruction Prosthesis to address proximal humeral bone loss

GPS Shoulder – the first platform shoulder navigation system

VERASENSE™ Wireless Humeral Load Sensor for rTSA, in partnership with OrthoSensor (2020) - the first commercially available load sensor in the shoulder

Predict+®, in partnership with KenSci (2020) - the first machine learning-based clinical decision support tool for the shoulder

Humeral Augmented Tray (2021) – the first rTSA to address posterior proximal humeral bone loss by facilitating metallic replacement of the tuberosity

Equinoxe Laser Cage Glenoid: the next generation cage glenoid




# ZERO REVISIONS for poly wear or lysis over 10 years<sup>1</sup>

**equinoxe**

By the Numbers

U.K. & Australian  
registries

9,136 aTSA/rTSAs  
over 10 years



In addition to our database, the largest registries in the world also tell the Equinoxe story.

According to data from the U.K. and Australian registries, the Equinoxe Shoulder System demonstrates low rates of failure for both aTSA and rTSA designs over a 10-year period. In addition, there were zero reported revisions for poly wear or lysis.

# The value of shoulder replacement is increasing.<sup>2</sup>

Diving deep into our database, both aTSA and rTSA prostheses demonstrated positive clinical results over 15 years, irrespective of the year of implantation, in a longitudinal analysis.

This study also highlighted the economic factors impacting shoulder surgery. While Equinoxe implant prices continue to decrease, clinical outcomes are improving, highlighting the value of shoulder replacement (especially rTSA) despite the cost of adding new technologies like the cage glenoid, GPS shoulder navigation, and more.



# equinox

By the Numbers<sup>2</sup>

Equinox prices  
are decreasing, but  
clinical outcomes  
are improving

•  
4,968 TSAs over  
15 years

•  
Data from six  
high-volume  
clinical sites







# The Premier Glenoid Solution: Equinoxe Cage Glenoid<sup>3</sup>

## equinoxe

By the Numbers

1,802 aTSA glenoids

- **Lower revision, aseptic loosening and radiolucent lines for the cage glenoid**

Another study from our database explores our wide range of glenoid solutions. It demonstrates that our aTSA glenoid components are a reliable treatment option from short to long-term.

It also explores results between our peg, keel and cage glenoids to patients with cemented peg and keel glenoids. Our cage glenoid showed:

- Lower revision rates
- Lowest rate of aseptic loosening
- Significantly lower rates of radiolucent glenoid lines
- Significantly fewer complications and revisions

# Next Generation Cage Glenoid

Our original cage glenoid launched in 2011 and performed beyond the required ASTM testing standards for aTSA glenoids.<sup>4</sup> With our newest design, we went even further.

The Laser Cage Glenoid went through extreme preclinical testing:<sup>5</sup>

- Cyclic testing was performed on a completely unsupported extra-large 16-degree augmented glenoid with a 5mm gap between the backside of the implant and the test fixture. The Laser Cage Glenoid withstood 200,000 cycles at 225lbs, well beyond the ASTM standard requirements for the number of cycles and implant seating.
- The Laser Cage Glenoid's bond strength between the metal cage/pegs and polyethylene was compared to the Legacy Cage Glenoid. Testing showed the Laser Cage Glenoid is 2X stronger in shear and 5X stronger in peg pull-off strength.



# equinox

By the Numbers<sup>5</sup>

Able to withstand  
225lbs for  
200,000 cycles  
(~20 years of use)

•  
2X stronger in  
shear resistance  
and 5X stronger  
in peg pull-off  
compared to the  
original Equinox  
Cage Glenoid

# An onlay implant for varying patient sizes.<sup>6</sup>

In a recent study from our database, researchers compared clinical outcomes from short to long-term follow-ups of patients of short and average heights who were treated with the Equinoxe Reverse Shoulder. The study showed:

- No significant differences between small and average-stature patients
- Small stature patients had three times lower revision rate compared to average-sized patients

## equinoxe

By the Numbers

2,154 rTSAs

**0.6% revision rate  
in smaller stature  
patients vs. 1.8%  
revision rate for  
average stature  
patients**




# An onlay device with market-defying results<sup>7</sup>

## equinox

By the Numbers

9,079 rTSA with 1.52%  
acromial/scapular  
fracture rate



As one of the first convertible systems on the market, the Equinox Reverse Shoulder is one of the most-studied onlay devices. In a recent study, researchers concluded:


- 1.52% rate of acromial and scapular fractures
- Patients with fractures were more likely older, female, diagnosed with rheumatoid arthritis and CTA, and less likely to have diabetes.

# Beyond implant solutions



**Implant innovation is just the beginning.**  
Exactech has a full suite of technologies to help you throughout the continuum of patient care.






From personalized patient outcome predictions to surgical planning to intraoperative navigation to patient text-messaging service to a mobile application for clinical exchange, we've got you covered.

“Without data, you’re just another person with an opinion.”

— W. Edwards Deming



#### References.

1. **Roche C., Flurin PH., Wright T., Zuckerman J.** Comparison of Survivorship & Failure Modes Between Anatomic and Reverse Total Shoulder Arthroplasty Across Multiple Government Joint Registries for a Single Platform Shoulder System. 2022.
2. **Roche C. et al.** Longitudinal Analysis of Shoulder Arthroplasty Clinical Outcomes and Value: a Comparative Assessment of Changes in Improvement Over 15 Years. 2022.
3. **Friedman R. et al.** Clinical and Radiographic Outcomes of Three Different Glenoid Designs with Anatomic Total Shoulder Arthroplasty at Short-Term, Mid-Term and Long-Term Follow-up. 2022.
4. **Roche C. et al.** Analysis of Glenoid Fixation with Anatomic Total Shoulder Arthroplasty in an Extreme Cyclic Loading Scenario. *Bulletin of the Hospital for Joint Diseases*. 2015; 73 (Suppl 1): S57-62.
5. **Vanasse T. Et al.** Extreme Bending Fatigue Testing of a New Hybrid Anatomic Glenoid Implant. ORS Poster. 2023.
6. **Elwell J. et al.** Is a Lateralized Onlay Humeral Reverse Total Shoulder Prosthesis Equally Effective in Treating Patients of Shorter Height: A Comparison of Patients of Short and Average Height at Short and Long-Term Follow-Up. 2022.
7. **Roche C. et al.** Impact of Accumulating Risk Factors on the Acromial and Scapular Fracture Rate After Reverse Total Shoulder Arthroplasty. *Journal of Shoulder and Elbow Surgery*. In Press.

\* *In Vitro* (bench) test results may not necessarily be indicative of clinical performance.



Exactech is proud to have offices and distributors around the globe.

For more information about Exactech products available in your country, please visit [www.exac.com](http://www.exac.com)

The products discussed herein may be available under different trademarks in different countries. All copyrights, and pending and registered trademarks, are property of Exactech. This material is intended for the sole use and benefit of the Exactech sales force and physicians. It should not be redistributed, duplicated or disclosed without the express written consent of Exactech. ©2023 Exactech. 12-0003263 Rev. A 0123